Antonia Beitzen-Heineke

Antonia Beitzen-Heineke is a Medical Specialist in Internal Medicine, Hematology, and Oncology at the University Medical Center Hamburg-Eppendorf (UKE). She holds dual affiliations in the II. Medical Clinic and Polyclinic (Center for Oncology) and the Institute of Tumor Biology within the Center for Experimental Medicine. Her expertise spans oncology, hematology, and hemostaseology, with a focus on cardio-oncology, chemotherapy-induced toxicity, and coagulation disorders in cancer patients.

Her research emphasizes translational studies in tumor biology, including the molecular mechanisms of coagulation activation in acute myeloid leukemia and the role of AXL inhibition in myeloproliferative neoplasms. She also investigates long-term cardiovascular effects of cancer therapies, leveraging cardiac MRI for early detection of myocardial dysfunction.

Publications highlight her work on thrombosis in paroxysmal nocturnal hemoglobinuria, checkpoint inhibitor immunotherapy’s impact on hemostasis, and athlete cardiac adaptations. She collaborates with multidisciplinary teams in radiology, immunology, and pharmacology.

Her clinical roles involve managing patients with hematologic malignancies and complex coagulation pathologies. No scientific awards are explicitly noted, but her active research profile underscores contributions to cardio-oncology and thrombosis biology.